Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02536170 · ClinicalTrials.gov registry record · Phase 2
Arginine Therapy for Sickle Cell Disease Pain
A Phase 2 study of Sickle Cell Disease and Vaso-occlusive Pain Episode, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 3
- Study locations
NCT02536170 is a Phase 2 study of Sickle Cell Disease and Vaso-occlusive Pain Episode that has completed, run by Emory University. The registered enrollment target is 108 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (63% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT02536170, a Phase 2 study of Sickle Cell Disease and Vaso-occlusive Pain Episode, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 3
- Study locations
Study Summary
The aim of this study is to determine whether giving extra arginine, a simple amino acid, to patients with sickle cell disease seeking treatment for a pain crisis (vaso-occlusive painful events (VOE) will decrease pain scores, decrease the need for pain medications or decrease length of hospital stay or emergency department visit. Funding Source - FDA OOPD.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG L-arginine
- DRUG L-arginine Loading Dose
Study Locations (3)
Georgia
- Children's Healthcare of Atlanta at Hugh Spalding - Atlanta
- Children's Healthcare of Atlanta at Egleston - Atlanta
- Children's Healthcare of Atlanta at Scottish Rite - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2016-02 |
| Est. Completion | 2021-02-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02536170
The ClinicalTrials.gov registry entry for NCT02536170 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (63% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02536170 reports 3 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT02536170 about?
NCT02536170 is a clinical study titled "Arginine Therapy for Sickle Cell Disease Pain". The aim of this study is to determine whether giving extra arginine, a simple amino acid, to patients with sickle cell disease seeking treatment for a pain crisis (vaso-occlusive painful events (VOE) will decrease pain scores, decrease the need for pain medications or decrease length of hospital sta...
What is the current status of trial NCT02536170?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2016-02. Estimated completion is 2021-02-21.
What conditions does trial NCT02536170 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Vaso-occlusive Pain Episode.
What interventions are being tested in trial NCT02536170?
The interventions under investigation include: Placebo (OTHER), L-arginine (DRUG), L-arginine Loading Dose (DRUG).
Who is sponsoring clinical trial NCT02536170?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02536170 being conducted?
This trial has 3 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.